Use of fosfomycin compared with ceftriaxone and meropenem for the treatment of urinary tract infections due to multidrug-resistant Escherichia coli (the FOREST study): Critically appraised article
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.163.1948Keywords:
Fosfomycin, Ceftriaxone, Meropenem, Escherichia coli, Urinary Tract InfectionsAbstract
Presentation: In this article, we present our critical assessment of a pragmatic clinical trial published in the Jama Network Open journal in the year 2022. Study conclusions: The study fails to demonstrate the non-inferiority of 4g of intravenous disodium fosfomycin every 6 hours over 60 minutes compared to ceftriaxone (1g of intravenous ceftriaxone every 24 hours over 2-4 minutes) or, if resistant to ceftriaxone, meropenem (1g of intravenous meropenem every 8 hours over 15-30 minutes). Critical comment: The article is relevant because bacterial resistance is currently of interest for the proper management of urinary tract infections. Therefore, alternatives that are not empirically used are being sought. However, the study has limitations such as not reaching the calculated sample size, having a low margin of non-inferiority, and the lack of blinding in the intervention.
Downloads
Metrics
References
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, et al. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(1):e2137277. doi: 10.1001/jamanetworkopen.2021.37277
Ramírez-Castillo FY, Moreno-Flores AC, Avelar-González FJ, Márquez-Díaz F, Harel J, Guerrero-Barrera AL. An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. Ann Clin Microbiol Antimicrob. 2018;17(1):34. doi: 10.1186/s12941-018-0286-5
Guzmán M, Salazar E, Cordero V, Castro A, Villanueva A, Rodulfo H, et al. Multidrug resistance and risk factors associated with community-acquired urinary tract infections caused by Escherichia coli in Venezuela. Biomédica. 2019;39:96-106. 10.7705/biomedica.v39i2.4030
Ghosh A, Bandyopadhyay D, Koley S, Mukherjee M. Uropathogenic Escherichia coli in India—an Overview on Recent Research Advancements and Trends. Appl Biochem Biotechnol. 2021;193(7):2267-96. doi: 10.1007/s12010-021-03521-z
Pouwels KB, Yin M, Butler CC, Cooper BS, Wordsworth S, Walker AS, et al. Optimising trial designs to identify appropriate antibiotic treatment durations. BMC Med. 2019;17:115. doi: 10.1186/s12916-019-1348-z
Tandogdu Z, Wagenlehner FME. Global epidemiology of urinary tract infections. Curr Opin Infect Dis. 2016;29(1):73-9. doi: 10.1097/QCO.0000000000000228
Tamma P, Aitken S, Bonomo R, Mathers A, van Duin D, Clancy C. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0 [Internet]. [citado 7 de abril de 2023]. Disponible en: https://www.idsociety.org/practice-guideline/amr-guidance-2.0/www.idsociety.org/practice-guideline/amr-guidance-2.0
Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019;69(12):2045-56. doi: 10.1093/cid/ciz181
Tamma PD, Bonomo RA, Stiefel U. The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante’s Forest Dark. JAMA Netw Open. 2022;5(1):e2138691.
Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928-d5928. doi: 10.1136/bmj.d5928
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, et al. Trial Protocol - Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(1):e2137277.
European Medicines Agency. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. 2021; Disponible en: https://www.ema.europa.eu/en/documents/scientific-guideline/addendum-guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections_en.pdf
Beecher C, Duane S, Vellinga A, Murphy AW, Cormican M, Smyth A, et al. COSUTI: A Core Outcome Set (COS) for Interventions for the Treatment of Uncomplicated Urinary Tract Infection (UTI) in Adults. Antibiotics. 2022;11(12):1846. doi: 10.3390/antibiotics11121846
Williamson PR, Altman DG, Blazeby JM, Clarke M, Devane D, Gargon E, et al. Developing core outcome sets for clinical trials: issues to consider. Trials. 2012;13:132. doi: 10.1186/1745-6215-13-132
Duane S, Beecher C, Vellinga A, Murphy AW, Cormican M, Smyth A, et al. A systematic review of the outcomes reported in the treatment of uncomplicated urinary tract infection clinical trials. JAC-Antimicrob Resist. 2022;4(2):dlac025. doi: 10.1093/jacamr/dlac025
Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, Morales IM, Palacios-Baena ZR, Hernández-Torres A, et al. Supplementary material - Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(1):e2137277.
Iarikov D, Wassel R, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infect Dis Ther. 2015;4(4):433-58.
Abdallah TAK, Elajez R, Ibrahim TB, Alimam AB, Omrani AS. Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections. J Infect Public Health. 2021;14(11):1620-2. doi: 10.1016/j.jiph.2021.09.025
Grabein B, Graninger W, Baño JR, Dinh A, Liesenfeld DB. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017;23(6):363-72. doi: 10.1016/j.cmi.2016.12.005
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Frank Zela-Coila, Sonia Vizcarra-Jiménez, Alvaro Taype-Rondan
This work is licensed under a Creative Commons Attribution 4.0 International License.
